Gen-Probe suffers US setback for fully automated NAT (Nucleic Acid Test) blood screening tech
This article was originally published in Clinica
Shares in Gen-Probe fell by almost 10% last week after the US FDA decided not to approve what could have been the first fully automated, high-throughput nucleic acid test (NAT) system for blood screening in the US. Moreover, the company's failure to gain 510(k) marketing clearance for its Procleix TIGRIS laboratory system for screening donated blood samples meant that it also forfeited, temporarily, on a $10m milestone payout from marketing partner Chiron.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.